Cherissa Jackson’s voice radiates confidence and compassion. She’s thoughtful, eloquent, and seems to have a purity of purpose that’s rare in American society. While she spreads her time between numerous projects, she unifies her focus by thinking about her three Ps: passion, purpose, and people. She applies this theme to every endeavor, and it’s most apparent in her work with We DeCode, a venture she launched in early 2022 to bring precision wellness to its clients.
We Decode is a DNA-testing service specializing in predictive, customized analysis. While Jackson doesn’t market We Decode DNA kits as “cannabis kits,” she is offering a unique insight into the interaction between cannabis and an individual’s endocannabinoid system based on genomic profile. We Decode uses patented technology to inform clients which cannabinoid formulations are most effective for their specific genetic profile. Do you need more CBD and less THC? We Decode can tell you. The company also pairs these insights with peer-reviewed research studies about cannabinoids or genomic markers so clients understand what their body needs and how to approach those needs with care providers.
Jackson created the company after a discussion with a fellow veteran who had
